Beyond Circulating Tumor DNA for Efficacy: Can We Use Cell-Free DNA to Detect and Monitor Toxicity Signals?
Yiqing Zhao, John Gallon, Max H Kushner, Brad Jakubison, Jorge S Reis-Filho, Darren Hodgson, Julia Elvin, Yuval Dor, James Hadfield · 2026
Read Beyond Circulating Tumor DNA for Efficacy: Can We Use Cell-Free DNA to Detect and Monitor Toxicity Signals? by Yiqing Zhao, John Gallon, Max H Kushner, Brad Jakubison, Jorge S Reis-Filho, Darren Hodgson, Julia Elvin, Yuval Dor, James Hadfield (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13200888.txt.
Description
Yiqing Zhao and eight co-authors ask whether DNA floating free in the blood can warn doctors about harm from cancer drugs, in a 2026 review-style paper. Tests based on tumor DNA in blood already help track how well a treatment works.
Harm from treatment is now found with scans, tissue samples, or standard blood tests. Each of those has limits: samples are invasive, and blood tests can miss early damage or flag the wrong organ. The authors argue that free DNA shed by injured organs could give an earlier, wider warning across many tissues at once. Such a test would be useful in early drug trials, where new harms are unknown. The paper maps what is known and what still needs proof before clinics could rely on it.
Catalog record
| CREATOR | Yiqing Zhao, John Gallon, Max H Kushner, Brad Jakubison, Jorge S Reis-Filho, Darren Hodgson, Julia Elvin, Yuval Dor, James Hadfield |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 20 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |